- Home
- MEGL vs SBFM Comparison
MEGL vs SBFM Comparison
Compare MEGL & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MEGL | SBFM |
|---|---|---|
| Founded | 2016 | 2006 |
| Country | Hong Kong | United States |
| Employees | N/A | 50 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1M | 4.9M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | MEGL | SBFM |
|---|---|---|
| Price | $1.17 | $1.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 13.1K | ★ 37.9K |
| Earning Date | 04-10-2026 | 04-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $40.47 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.87 | $0.95 |
| 52 Week High | $2.62 | $2.43 |
Technical Indicators
Market Signals| Indicator | MEGL | SBFM |
|---|---|---|
| Relative Strength Index (RSI) | 56.93 | 56.59 |
| Support Level | $1.16 | $1.05 |
| Resistance Level | $1.36 | $1.24 |
| Average True Range (ATR) | 0.06 | 0.03 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 36.68 | 80.94 |
Price Performance
Historical ComparisonAbout MEGL Magic Empire Global Limited
Magic Empire Global Ltd is a financial services provider in Hong Kong which principally engage in the provision of corporate finance advisory services and underwriting services. The companys offerings mainly comprise of IPO sponsorship services, Financial advisory and independent financial advisory services, Compliance advisory services, Underwriting services, Corporate service.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.